Blueprint
 
    

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 7, 2016
 
PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
 
Maryland
 
001-14494
 
33-0724736
(State or other jurisdiction  of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
10 North Park Place, Suite 201
Morristown, NJ
 
 
07960
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (800) 793-2145
 
__________________________________________________________________
  (Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
☐
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
☐
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
 
☐
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
 
Item 8.01. Other Events.
 
On July 7, 2016, Pernix Therapeutics Holdings, Inc. issued a press release regarding a corporate restructuring. A copy of the press release is attached hereto as Exhibit 99.1.
 
Item 9.01    Financial Statements and Exhibits
 
(d)      Exhibits.
 
Exhibit Number
 
 Description
 
 
 
 
Press release by Pernix Therapeutics Holdings, Inc. dated July 7, 2016.
 
 
2
 
 
SIGNATURE
 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PERNIX THERAPEUTICS HOLDINGS, INC.
 
 
 
 
 
Dated:  July 7, 2016
By:
 /s/ Sanjay Patel
 
 
 
Sanjay Patel
 
 
 
Chief Financial Officer
 
 
 
 
 
 
 
3